Neurocrine Biosciences, Inc.

NasdaqGS:NBIX Stock Report

Market Cap: US$12.9b

Neurocrine Biosciences Past Earnings Performance

Past criteria checks 4/6

Neurocrine Biosciences has been growing earnings at an average annual rate of 12.2%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 21% per year. Neurocrine Biosciences's return on equity is 14.2%, and it has net margins of 17.2%.

Key information

12.2%

Earnings growth rate

10.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate21.0%
Return on equity14.2%
Net Margin17.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08
Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Recent updates

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Oct 10

The Play On Neurocrine Biosciences

Oct 02

Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data

Aug 28

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Jul 28
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Jul 09

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08
Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Apr 27
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Apr 25

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Mar 31
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

Feb 11

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Jan 07
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Dec 11
Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Sep 12
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Jun 08
We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Revenue & Expenses Breakdown

How Neurocrine Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:NBIX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,2433869240
30 Jun 242,1203399080
31 Mar 241,9823708880
31 Dec 231,8872508880
30 Sep 231,7841918520
30 Jun 231,6731768340
31 Mar 231,599647950
31 Dec 221,4891557530
30 Sep 221,389587260
30 Jun 221,297126950
31 Mar 221,208716550
31 Dec 211,134905830
30 Sep 211,0694455330
30 Jun 211,0323654910
31 Mar 211,0454024450
31 Dec 201,0464074330
30 Sep 201,042934280
30 Jun 201,0062054000
31 Mar 208871773840
31 Dec 19788373540
30 Sep 19675213220
30 Jun 19605182980
31 Mar 19519-392780
31 Dec 18451212490
30 Sep 184141023617
30 Jun 18323-5222032
31 Mar 18233-10620048
31 Dec 17162-1431700
30 Sep 1767-19413790
30 Jun 176-22011188
31 Mar 170-2008490
31 Dec 1615-1416858
30 Sep 1615-1265357
30 Jun 1615-1234758
31 Mar 1615-1073952
31 Dec 1520-893248
30 Sep 1520-792944
30 Jun 1520-602237
31 Mar 1520-501934
31 Dec 140-611832
30 Sep 141-521629
30 Jun 141-471527
31 Mar 142-461426
31 Dec 133-461325

Quality Earnings: NBIX has a large one-off loss of $168.1M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: NBIX's current net profit margins (17.2%) are higher than last year (10.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NBIX's earnings have grown by 12.2% per year over the past 5 years.

Accelerating Growth: NBIX's earnings growth over the past year (102%) exceeds its 5-year average (12.2% per year).

Earnings vs Industry: NBIX earnings growth over the past year (102%) exceeded the Biotechs industry 16.6%.


Return on Equity

High ROE: NBIX's Return on Equity (14.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies